.Attributes Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ state-of-the-art bosom cancer cells and energetic or even steady mind metastases showed steady intracranial activity and also wide spread efficiency of T-DXd.